A week of UK deals exemplifies China’s growing role in global biotech investment
We’ve reported about the biotech boom in China for a while now: both the domestic market for new drugs, and innovative therapies primed to come out of the country. But there’s more to that story, as China plants flags globally through investments. Just ask the UK.
During Theresa May’s three-day visit in China last week, the British prime minister’s team seized the opportunity to enlist Chinese support for UK biotech. Deals were signed: Chinese investors will infuse $1.3 billion in two British venture capital firms for their life science investments; new buildings will spring up at Cambridge Science Park thanks to a $277 million (£200 million) joint venture between Cambridge’s Trinity College and Tus Park, a branch of prestigious TsingHua University.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.